First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis

被引：0
|
作者：
Bobo Zheng
Xin Wang
Mingtian Wei
Quan Wang
Jiang Li
Liang Bi
Xiangbing Deng
Ziqiang Wang
机构：
[1] Sichuan University,Department of Gastrointestinal Surgery, West China Hospital
[2] First Affiliated Hospital of Xi’an Jiaotong University,Department of Gastroenterology
[3] The Fourth Military Medical University,Digestive disease hospital, Xijing Hospital
[4] Chinese Academy of Medical Sciences and Peking Union Medical College,National Cancer Center/Cancer Hospital
来源：
BMC Cancer | / 19卷
关键词：
First line; Cetuximab; Bevacizumab; Wild type; Metastatic colorectal cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis
    Zheng, Bobo
    Wang, Xin
    Wei, Mingtian
    Wang, Quan
    Li, Jiang
    Bi, Liang
    Deng, Xiangbing
    Wang, Ziqiang
    BMC CANCER, 2019, 19 (1)
  • [2] Tolerability on Serious Adverse Events of First-Line Bevacizumab and Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
    Han, Yu Na
    Choi, Yeo Jin
    Rhie, Sandy Jeong
    HEALTHCARE, 2022, 10 (02)
  • [3] Tumor sidedness and efficacy of first-line therapy in patients with RAS/BRAF wild-type metastatic colorectal cancer: A network meta-analysis
    Wu, Chih-Chien
    Wang, Jui-Ho
    Lin, Pei-Chin
    Liang, Chun-An
    Huang, Ching-Ying
    Lien, Han-Chu
    Chen, Chung-Yu
    Chou, Kang-Ju
    Su, Yi-Chia
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2020, 145
  • [4] Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England
    Tikhonova, Irina A.
    Huxley, Nicola
    Snowsill, Tristan
    Crathorne, Louise
    Varley-Campbell, Jo
    Napier, Mark
    Hoyle, Martin
    PHARMACOECONOMICS, 2018, 36 (07) : 837 - 851
  • [5] Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England
    Irina A. Tikhonova
    Nicola Huxley
    Tristan Snowsill
    Louise Crathorne
    Jo Varley-Campbell
    Mark Napier
    Martin Hoyle
    PharmacoEconomics, 2018, 36 : 837 - 851
  • [6] Chemotherapy plus panitumumab/cetuximab versus chemotherapy plus bevacizumab in wild-type KRAS/RAS metastatic colorectal cancer: a meta-analysis
    Zhang, Chengren
    Liu, Lili
    Lv, Yaochun
    Li, Jingjing
    Cao, Cong
    Lu, Jiyong
    Wang, Shuai
    Du, Binbin
    Yang, Xiongfei
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (12) : 1333 - 1348
  • [7] Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis
    Baraniskin, Alexander
    Buchberger, Barbara
    Pox, Christian
    Graeven, Ulli
    Holch, Julian W.
    Schmiegel, Wolff
    Heinemann, Volker
    EUROPEAN JOURNAL OF CANCER, 2019, 106 : 37 - 44
  • [8] CETUXIMAB IN THE FIRST-LINE TREATMENT OF RAS WILD-TYPE METASTATIC COLORECTAL CANCER WITH LIVER-LIMITED DISEASE
    Souza, P., V
    Zanini, F. E.
    Biglia, L., V
    Kim, H. S.
    Fahham, L.
    VALUE IN HEALTH, 2017, 20 (09) : A875 - A875
  • [9] Efficacy of Bevacizumab in the First-Line Treatment of Patients with RAS Mutations Metastatic Colorectal Cancer: a Systematic Review and Network Meta-Analysis
    Zhou, Mingyi
    Yu, Ping
    Qu, Jinglei
    Chen, Ying
    Zhou, Yang
    Fu, Lingyu
    Zhang, Jingdong
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2016, 40 (1-2) : 361 - 369
  • [10] Quality of Life Analysis in Patients With RAS Wild-Type Metastatic Colorectal Cancer Treated With First-Line Cetuximab Plus Chemotherapy
    Yamaguchi, Kensei
    Ando, Masahiko
    Ooki, Akira
    Beier, Frank
    Guenther, Silke
    von Hohnhorst, Philipp
    Van Cutsem, Eric
    CLINICAL COLORECTAL CANCER, 2017, 16 (02) : E29 - E37
12345